XTANDI® (Enzalutamide)

December 27th, 2019

The FDA on December 16, 2019 approved XTANDI® for patients with metastatic Castration-Sensitive Prostate Cancer (mCSPC). XTANDI® is a product of Astellas Pharma Inc.


XTANDI® (Enzalutamide)

July 25th, 2018

The FDA on July 13, 2018 approved XTANDI® for patients with Castration-Resistant Prostate Cancer (CRPC). This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. XTANDI® was previously approved for the treatment of patients with metastatic CRPC. XTANDI® is a product of Astellas Pharma US, Inc.


XTANDI® (Enzalutamide)

November 12th, 2012

The FDA on August 31, 2012 approved XTANDI® (Enzalutamide) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI® capsules are a product of Medivation, Inc. and Astellas Pharma US, Inc.